ClinicalTrials.Veeva

Menu

Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies (BASIC)

U

University Hospital, Angers

Status

Begins enrollment in 1 month

Conditions

Severe Asthma

Treatments

Other: Intake Interview with the Patient
Other: Initial assesment interwiew

Study type

Observational

Funder types

Other

Identifiers

NCT07856407
49RC26_0294

Details and patient eligibility

About

Severe asthma is a debilitating disease that affects every aspect of patients' lives: daily life, work, social life, family life, and marital life. The advent of biologic therapies has transformed these patients' quality of life by improving asthma control, access to care, and overall quality of life. But how do patients actually experience this transformation in their lives? What has actually changed for them, based on their own perceptions? Investigator hypothesize that a hypothetical-deductive qualitative study with a methodology focused on each patient's individual situation will allow to better explore the changes that have occurred in these patients' lives.

The BASIC Study aims to understand, through semi-structured interviews, how the lives of patients on biologic therapy have evolved. Patient therapeutic education is an integral part of the care provided to patients with severe asthma in the Pulmonology Department at Angers University Hospital. This therapeutic education is truly centered on patients' needs thanks to a methodology designed to reveal units of meaning. The BASIC study will employ the same methodology to analyze patients' life situations in order to better understand the changes they perceive while on biologic therapy, as well as their new educational needs. The results would make it possible to assess the qualitative effectiveness of biologic therapies from a unique patient-centered perspective, as well as to identify new educational needs among these patients. Thus, the current therapeutic education program could be enhanced.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients.
  • Patients with severe asthma who have been receiving targeted therapy (with omalizumab, benralizumab, mepolizumab, dupilumab, or tezepelumab) for at least 6 months, with no upper limit on the duration of treatment.
  • Able to understand the informed consent form and willing to consent to participate in a recorded semi-structured interview, as well as to the anonymized processing of their data.

Exclusion criteria

Any person

  • Who refuses to participate in the research.
  • Who is unable to travel to participate in an in-person interview.
  • Who is under legal guardianship or conservatorship.
  • Who does not speak French.
  • Who has asthma associated with a systemic disease (GEPA, ABPA, etc.).

Trial design

20 participants in 1 patient group

Simple group
Treatment:
Other: Initial assesment interwiew
Other: Intake Interview with the Patient

Trial contacts and locations

0

Loading...

Central trial contact

Anne PINEAU; Anne PINEAU

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems